Form 4: Tandem Diabetes COO Reports RSU Vesting & Tax Withholding

Tandem Diabetes Care's EVP & COO, Jean-Claude Kyrillos, reported the vesting of 3,636 restricted stock units and the withholding of 1,301 shares for tax obligations.

Summary

• Jean-Claude Kyrillos, Executive Vice President & Chief Operating Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions related to his beneficial ownership.
• On October 15, 2025, 3,636 restricted stock units (RSUs) vested and converted into common stock.
• Concurrently, 1,301 shares of common stock were disposed of at a price of $14.75 per share to satisfy tax withholding requirements related to the RSU vesting.
• No shares were sold by Mr. Kyrillos; the disposition was solely for tax purposes.
• Following these transactions, Mr. Kyrillos beneficially owns 22,384 shares of common stock directly.
• He also holds 25,453 derivative securities in the form of restricted stock units.
• The RSUs were awarded on July 15, 2024, under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.
• The vesting schedule for these RSUs includes 33% vesting on July 15, 2025, with the remaining shares vesting in eight equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to executive compensation (RSU vesting and tax withholding). It does not contain information that would significantly alter the perception of the company's operational performance, financial health, or strategic outlook, thus indicating a neutral sentiment.

Positives

• The vesting of 3,636 restricted stock units represents a scheduled compensation event for the EVP & COO, indicating continued executive alignment with shareholder interests through equity ownership.

Negatives

• 1,301 shares of common stock were withheld to cover tax obligations, resulting in a slight reduction in the executive's direct common stock holdings from 23,685 to 22,384 shares.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape within the diabetes care sector.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine executive compensation event, reflecting the planned equity incentives for a key executive.

Next Steps

• The remaining 25,453 Restricted Stock Units held by Mr. Kyrillos will continue to vest in eight equal quarterly installments following the initial 33% vesting on July 15, 2025.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the vesting of restricted stock units and subsequent tax withholding for a key executive. It does not provide any new material information regarding Tandem Diabetes Care's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to evaluate the company based on its core business fundamentals and broader market conditions.

Keywords

TNDM, Tandem Diabetes Care, Form 4, Insider Transaction, RSU, Restricted Stock Unit, Executive Compensation, Jean-Claude Kyrillos